Obesity is regarded as a major public health concern, owing to the multifaceted factors involved in metabolic complications rooted in multifactorial causes (e.g., environmental toxicity or genetic abnormality), as well as the unmet landscape of the health-care system in search of therapeutic or prevention methods. Evidence that supports Omics as a strategic tool of systemic biology is being used to define the wiring of the molecular circuit in metabolic malfunctions, as well as the evaluation of metabolic modulators such as synthetic drugs, stem cell replacement, and natural secondary metabolites derived from various sources. The link between the nutritional environment and cellular/genetic processes is referred to as nutritional genomics or Nutrigenomics. Its goal is to figure out how nutrition affects a person's genes and health. Nutrigenomics strives to give a genetic understanding of how common food ingredients (i.e., nutrition) modify the expression or structure of an individual's genetic makeup, hence affecting the balance of health and sickness. Furthermore, enhancing detection capabilities from patient clinical samples and monitoring illness progression in reserve populations, who may be at a higher risk of disease susceptibility due to numerous micro- and macro-environmental variables, remains a preventative thread in public health informatics. By utilising the omics platform, which includes epigenetics, metabolomics, nutrigenomics, transcriptomics, pharmacogenomics, and genomics, molecular-based detection systems can forecast evolving disease in terms of key molecule modifications that may contribute to disease pathogenesis and reflect heredity, such as quantitative trait loci, polymorphism, and epigenetic modification. Furthermore, a customised or personalised approach to treating metabolic disease could be applied by building a person's health algorithm in conjunction with a molecular chain-based surveillance and prevention system. To encourage effective biomarker discoveries in the field of molecular therapy and early detection target molecules in obesity, early diagnostic tools as a potential strategy has inspired us in clinical validation and assessment to improve prevention/treatment outcomes for a better translation medicine process. In this short review, we aim to better understand the interaction and connectivity between risks and metabolic disorders like obesity by utilising the molecular drive platform that OMICS technologies are worthy of developing a clinical assessment with regard to diagnosing, predicting, and treating metabolic disease chains (i.e., initiation, progress, and determination) and defining causative molecule-based wiring on host defence machinery after exposure to various unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown Nutrigenomics, as a crucial strategical method to detecting genetic variation or disclosing faults of the host defence system in metabolic disorders, can be used not only to assess one's risk for obesity, but also to treat obesity through the creation of individualised diet regimens.
Author(s) Details:
S. Bartley
Department of Public Health, Division of Environmental Health Science, New
York Medical College, Valhalla NY 10595, USA.
H. H. Cho,
College of Veterinary Medicine, Gyeongsang National University, Jiju Daero 501,
Jinju-City, Gyeongsangnamdo, 660-701, Korea.
D. E. Heck,
Department of Public Health, Division of Environmental Health Science, New York
Medical College, Valhalla NY 10595, USA.
J. H. Cho,
College of Veterinary Medicine, Gyeongsang National University, Jiju Daero 501,
Jinju-City, Gyeongsangnamdo, 660-701, Korea.
H. D. Kim,
Department of Public Health, Division of Environmental Health Science, New York
Medical College, Valhalla NY 10595, USA.
Please see the link here: https://stm.bookpi.org/ETDHR-V4/article/view/6049
No comments:
Post a Comment